BAIT
P2RY6
P2Y6, PP2891
pyrimidinergic receptor P2Y, G-protein coupled, 6
GO Process (1)
GO Function (1)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
PTPRJ
CD148, DEP1, HPTPeta, R-PTP-ETA, SCC1
protein tyrosine phosphatase, receptor type, J
GO Process (17)
GO Function (9)
GO Component (8)
Gene Ontology Biological Process
- contact inhibition [NAS]
- negative regulation of MAP kinase activity [IDA]
- negative regulation of T cell receptor signaling pathway [IDA, IMP]
- negative regulation of cell growth [IDA]
- negative regulation of cell migration [IDA]
- negative regulation of cell proliferation [IDA]
- negative regulation of epidermal growth factor receptor signaling pathway [IMP]
- negative regulation of platelet-derived growth factor receptor signaling pathway [IDA]
- negative regulation of protein kinase B signaling [IMP]
- negative regulation of vascular permeability [IDA]
- peptidyl-tyrosine dephosphorylation [IDA, IMP]
- platelet-derived growth factor receptor signaling pathway [IMP]
- positive chemotaxis [IDA]
- positive regulation of cell adhesion [IMP]
- positive regulation of focal adhesion assembly [IMP]
- positive regulation of protein kinase B signaling [IMP]
- regulation of cell adhesion [IMP]
Gene Ontology Molecular Function- beta-catenin binding [IPI]
- delta-catenin binding [IPI]
- gamma-catenin binding [IPI]
- mitogen-activated protein kinase binding [IPI]
- phosphatase activity [IDA, IMP]
- platelet-derived growth factor receptor binding [IPI]
- protein binding [IPI]
- protein kinase binding [IPI]
- protein tyrosine phosphatase activity [IDA, IMP]
- beta-catenin binding [IPI]
- delta-catenin binding [IPI]
- gamma-catenin binding [IPI]
- mitogen-activated protein kinase binding [IPI]
- phosphatase activity [IDA, IMP]
- platelet-derived growth factor receptor binding [IPI]
- protein binding [IPI]
- protein kinase binding [IPI]
- protein tyrosine phosphatase activity [IDA, IMP]
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -3.493 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID